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Background: HPV vaccination reduces the risk of cervical cancer. Uptake however, of the ‘catch-up’ campaign in
England for 17-18 year old girls is below the 80% NHS target. The aim of this randomized controlled trial is to
assess the impact of financial incentives on (a) the uptake and completion of an HPV vaccination programme and
(b) the quality of the decisions to undertake the vaccination.
Method/Design: One thousand (n = 1000) 16-18 year-old girls will be invited to participate in an HPV vaccination
programme: Five-hundred (n = 500) will have received a previous invitation to get vaccinated but will have failed to
do so (previous non-attenders) and 500 will not have previously received an invitation (first-time invitees). Girls will
be randomly selected from eligible participants who are registered with a GP in areas covered by the Birmingham
East and North (BEN) and Heart of Birmingham Primary Care Trusts. The two samples of girls will be randomised to
receive either a standard vaccination invitation letter or an invitation letter including the offer of vouchers worth
£45 for receiving three vaccinations. Girls will also complete a questionnaire to assess the quality of their decisions
to be vaccinated. The primary outcome will be uptake of the 1st and 3rd vaccinations. The secondary outcome will
be the quality of the decisions to undertake the vaccination, measured by assessing attitudes towards and
knowledge of the HPV vaccination.
Discussion: The key results will be: a) the effectiveness of financial incentives in increasing uptake of the 1st and 3rd
vaccinations; b) the role of participants’ socio-economic status in the moderation of the impact of incentives on
uptake; and c) the impact of incentives on the quality of decisions to undertake the HPV vaccinations.
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Human Papillomavirus (HPV) is an ubiquitous sexually
transmitted virus that could lead to cervical cancer [1,2].
HPV vaccines help prevent infection by some of the
most common forms of HPV that are associated with
later development of cancer [3,4]. The HPV immunisa-
tion process takes six elapsed months and is conducted
in three stages: 1st vaccine, 2nd vaccine two months later,
and a 3rd vaccine six months after the first vaccination.
Completion of all three vaccinations is necessary to ef-
fectively reduce the risk of cervical cancer [5]. The* Correspondence: theresa.marteau@kcl.ac.uk
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reproduction in any medium, provided the ordegree of protection afforded by incomplete immunisa-
tion is currently unknown [6].
Since September 2008 a national programme has
started in England and Wales aiming to vaccinate girls
aged 12-13 against HPV. A two-year ‘catch-up’ campaign
that offers the HPV vaccine to 17-18 year old girls has
also been initiated. The objective of these HPV vaccin-
ation programmes is to provide three doses of the HPV
vaccine to females before they become sexually active,
when the risk of HPV infection and subsequent cervical
cancer development increases. It is estimated that if this
objective is met and vaccination coverage is sufficiently
high (80% of the target population), up to 400 deaths
per year in England could be prevented [7]. Although
the national programme in England aimed at 12-
13 year-old girls has resulted in high uptake (88.1%l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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vaccination), the uptake rates for the “catch-up” cam-
paign in England (targeting 17-18 year olds) have been
lower, with 62.2% of the target group receiving the first
dose and 31.8% the third [7].
Offering girls financial incentives to undergo the HPV
vaccination could increase these uptake rates. Incentive
mechanisms are increasingly being considered and used
in health care policy in the UK and elsewhere in an at-
tempt to change health-related behaviour [8,9]. They are
most effective in changing ‘simple’, ‘one-off behaviours’
such as getting vaccinated [10-12]. Their effectiveness
however, has been predicted to vary with recipients’ level
of social deprivation. Specifically, it has been argued that
the most socially deprived should respond more to fi-
nancial incentives [13]. Most of the calls, to use incen-
tives in HPV vaccination programmes in the UK have so
far focused on incentivising those providing the vaccin-
ation (e.g. GPs) rather than vaccination recipients [14].
Their effectiveness therefore in this context is currently
unknown. Furthermore, no studies have assessed the
role of social deprivation in the moderation of their im-
pact on vaccination uptake.
Even if effective in improving uptake of the HPV na-
tional vaccination programme, the use of financial incen-
tives raises concerns about the possible adverse effects
they may have on the quality of people’s decisions to en-
gage in incentivised behaviours. For example, it has been
argued that the prospect of receiving a financial reward
could result in the risks associated with a particular
health behaviour being overlooked [15].To date, how-
ever, no known studies have assessed the mechanisms by
which financial incentives influence the decision-making
processes involved in engaging in an incentivised health
behaviour.
In summary, further research is needed to determine
the impact of financial incentives upon first, uptake of
the HPV vaccination, and second, the quality of recipi-
ents’ decisions to get vaccinated. Furthermore, research
is needed to determine the role of social deprivation in
the moderation of the impact of financial incentives on
uptake of vaccinations.
Objectives and hypotheses
The primary objectives of the present study are:
(a) To assess the impact of financial incentives on the
initial uptake (uptake of the first vaccination) and
completion rates (uptake of the third vaccination) of
an HPV vaccination programme.
(b) To assess the impact of financial incentives on the
quality of the decision to be vaccinated as measured
by attitudes towards and knowledge of the
vaccination.The secondary objective is:
(a) To assess whether the impact of financial incentives
on the initial uptake and completion rates of an
HPV vaccination programme is moderated by
participants’ levels of social deprivation.
Hypothesis I
Those offered financial incentives to get vaccinated
against HPV are more likely to receive the first and third
HPV vaccinations.
Hypothesis II
The effect of incentives on uptake of the first and third
vaccinations will be moderated by participants’ levels of
social deprivation, with larger effects of the incentives
being observed for the most socially deprived.
Hypothesis III
Offering financial incentives reduces the quality of deci-
sions to get vaccinated against HPV.
Methods/Design
Trial design
This is a randomised controlled trial in which two inde-
pendent samples of participants are separately rando-
mised to the offer of financial incentives for getting
vaccinated.
Participants
Participants will compromise of 16-18 year old girls, liv-
ing in Birmingham. To be included in the trial, girls
must fulfill the following inclusion criteria:
(a) Live in areas falling under the administration of the
Birmingham East and North (BEN) and the Heart
of Birmingham Primary Care Trusts
(b) Be registered with a GP within one of the two PCTs
(c) Be eligible to be vaccinated through the clinics
(Sutton Cottage, Partners in Health and Dove
Medical Centre)
(d) Not have been vaccinated against HPV before.
Half of the sample will consist of girls who have previ-
ously received an invitation to get vaccinated, but have
failed to attend the first appointment (previous non-
attenders). The remaining half will consist of girls who
have not yet received an invitation to attend the vaccin-
ation programme (first-time invitees).
Intervention
The components of the intervention used in the present
HPV vaccination programme are:
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All participants will receive letters inviting them to at-
tend their first HPV vaccination session. These will be
sent on behalf of the Birmingham East and North and
Heart of Birmingham Primary Care Trusts, and will in-
clude the date, time and location of the allocated
appointments.
Reminder text messages
Participants attending their first vaccination appoint-
ment will be asked to inform the researchers of their
mobile phone numbers. These will be used to send text
messages reminding them of their subsequent vaccin-
ation appointments. These will be sent during the inter-
vals between the first and second vaccinations and the
second and third vaccinations and two days prior to the
next session. An example of the wording of these mes-
sages is: “(Name), don’t forget your HPV jab today at
(time) at the (venue). Thank you”.
Offer of financial incentives
Participants from the two samples (i.e. previous-non
attenders and first-time invitees) allocated to the incenti-
vised groups will receive a modified version of the stand-
ard vaccination invitation letter, described above, which
will include the offer of vouchers worth £45 for receiving
the three vaccinations. Specifically, participants will be
informed that they will receive:
£20 for the first vaccination
£5 for the second vaccination
£20 for the third vaccination
Procedure
The trial will be run by the Birmingham East and
North Primary Care Trust in collaboration with
Healthy Incentives (www.healthyincentives.org.uk/, a
social enterprise arising as a result of a partnership be-
tween the Young Foundation and the Birmingham East
and North Primary Care Trust). The Birmingham East
and North PCT has employed the Birmingham Pri-
mary Care Shared Services Agency (BPCSSA) to do
the following: select participants to be included in the
trial; randomise them to each group and post the invi-
tation letters. Once the letters have been sent, the
BPCSSA will provide the Healthy Incentives team with
the details of all the participants who have been
invited, including their names, addresses, scheduled
vaccination dates, the participant group (previous non-
attender or previously not invited) and randomisation
group (incentive or not). The vaccinations for all indi-
viduals will take place at three community clinics. The
BPCSSA will schedule a number of ‘incentivised only’
sessions at these clinics to avoid any tensions causedby not incentivising all groups. Vaccinations will be car-
ried out by nurses working with Heart of Birmingham
(HOB). When attending their first vaccination session and
while waiting to get vaccinated, participants will be asked
to sign a consent form and complete a measure assessing
the quality of their decision to get vaccinated. They will
also be requested to select a date for their next vaccin-
ation. Receipt of each vaccination will be contingent on
completion of all the previous doses (i.e. in order to re-
ceive the 3rd vaccination participants will need to have
first completed the 1st and 2nd vaccinations), with no
skipping of doses being allowed. After receiving their vac-
cinations, participants in the incentivised groups will be
provided with the appropriate shopping vouchers. Two
days prior to their 2nd and 3rd vaccination sessions, the
Healthy Incentives team will send participants text mes-
sages reminding them of their appointments.
Participant recruitment and randomisation
To be included in the study, participants will be selected
randomly from a list of names of all girls aged 16-
18 years, meeting the above inclusion criteria (See
Figure 1). This list will be compiled by the Birmingham
Primary Care Shared Services Agency (BPCSSA), which
holds and controls all Birmingham patient data, from
the names of all 16-18 year old girls eligible to be vacci-
nated against HPV. The list will be sorted according to
whether girls have received a previous invitation to get
vaccinated but have failed to attend their first session or
have not previously received an invitation. BPCSSA will
randomly select 500 participants to be included in the
trial from each of these two sub-lists using the RAND()
function in Excel. Selected individuals from both the
samples will subsequently be separately randomised, via
the aforementioned technique, to receive one of two
invitations letters:
(a) A standard letter inviting them to attend their first
vaccination session (Additional file 1) or
(b) A modified invitation letter, which will include the
offer of vouchers worth £45 for receiving the three
vaccinations (Additional file 1)
This will result in the groups presented in Table 1
Outcomes
Uptake
Uptake of each vaccination by participants will be
recorded at the community clinics where vaccinations
will take place.
Social deprivation
Levels of social deprivation will be measured by using
participants’ postcodes to calculate Index of Multiple
Figure 1 Recruitment and randomisation of participants.
Mantzari et al. BMC Health Services Research 2012, 12:301 Page 4 of 6
http://www.biomedcentral.com/1472-6963/12/301Deprivation (IMD) scores. This is a measure of multiple
deprivation measured at the small area level, i.e. the
Lower Layer Super Output Area (LSOA). It is made up
of seven LSOA level domain indices, which relate to in-
come deprivation, employment deprivation, health
deprivation and disability, education skills and training
deprivation, barriers to housing and services, living en-
vironment deprivation, and crime. IMD scores range
from 0 to100, with higher scores indicating higher levels
of deprivation.
Informed choice
In order to assess whether the offer of financial incen-
tives undermines the quality of decisions to undertake
















incentives)validated measure of informed choice will be used [16].
This will consist of (Additional file 2):
1. Two items rated on a seven point scale, assessing
attitudes towards the HPV vaccination: “For me,
having the HPV vaccination is (a) 1: not at all good
−7: extremely good and (b) 1: not at all harmful-7:
extremely harmful.”
2. Three items assessing knowledge of the HPV
vaccination by requesting participants to determine
the validity (whether true or false) of three
statements relating to the vaccination: “If I have the
HPV vaccination: I am less likely to get cervical
cancer; I am less likely to get other sexually
transmitted diseases; I am less likely to get pregnant.”Sample size determination
According to the latest report from the Department of
Health on coverage of the HPV vaccinations [7], the aver-
age completion rate for the “catch-up” campaign target-
ing females aged 17-18 years in the Birmingham East &
North Primary Care Trust is 32.4%. Previous studies in-
vestigating the impact of financial incentives on uptake
of vaccinations have reported an avergage between-
group difference of approximately 8.5%: Specifically,
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take of the influenza vaccination with incentives (20.3%
(control group) vs 28.8% (incentivised group)) and Yok-
ley et al. [18] reported an avergage increase of 8.4% in
childhood immunisation across three time points with
the addition of inventives (at two weeks: 10.1% (control
group) vs. 22.5% (incentivised group); at 2 months: 22.7%
(control group) vs. 30.8% (incentivised group); at three
months: 26% (control group) vs 30.8% (incentivised
group)). Based on these figures, we expect financial
incentives in this study to increase completion (i.e. up-
take of the 3rd vaccination) of the HPV vaccination
programme by 8.5%, resulting in a completion rate of
40.9% by incentivised groups. To detect this difference
between arms using a two-tailed χ2 test at the 5% signifi-
cane level with 80% power, a sample of 1008 participants
is required (calculations performed in GPower 3.0); This
figure has been rounded off to the nearest whole number,
resulting in a required sample of 1000 participants (half
of whom consist of previous-non attenders and half of
whom, first-time invitees), giving 500 in each interven-
tion arm (See Table 1).
Evaluation
The evaluation of the financial incentive scheme will be
conducted by researchers at King’s College London,
Centre for the Study of Incentives in Health (CSI Health,
www.kcl.ac.uk/csihealth). Data relating to participants’
uptake of each of the three HPV vaccinations, along with
their postcodes, age and answers to the measure of
informed choice will be transferred by the Healthy
Incentives team to CSI Health researchers. All informa-
tion will be anonymised and kept securely. Data will be
transferred via email in password protected files. CSI
Health researchers will analyse the data with the aim of:
i) determining the impact of financial incentives on up-
take of the HPV vaccination and on the quality of girls’
decisions to get vaccinated; and ii) writing up and pub-
lishing the findings.
Statistical analysis
To assess the impact of the intervention on initial up-
take (i.e. the 1st vaccination) and completion of the
HPV vaccination programme (i.e. the 3rd vaccination)
logistic regressions will be performed separately for each
of the two samples, i.e. for girls who have not received
an invitation to get vaccinated before and those who
have received a previous invitation but have failed to at-
tend. To test the moderating effect of social deprivation
on the impact of the intervention, the interaction be-
tween IMD scores and intervention will be added to the
logistic regression models. To test whether there is a dif-
ference in the size of effect of the intervention in the
two samples, datasets will be combined and anotherlogistic regression conducted, in which whether partici-
pants have received an invitation to get vaccinated be-
fore or or not will be added as a predictor to the model,
along with the intervention. To test for differences in
the attrition rates between the 1st and 3rd vaccinations
between the invervention and control groups the χ2 test
will be used. Finally, differences in knowledge of the
HPV vaccination between intervention and control
group will be tested using the χ2 test, while differences
in attitudes towards the HPV vaccination will be exam-
ined via a one-way analysis of variance. All tests will be
assessed at the 5% level of significance.
Discussion
The results of the study will produce valuable informa-
tion regarding the potential effectiveness of financial
incentives in increasing uptake and completion of the
HPV vaccinations by teenage girls. The results will also
provide valuable information regarding the validity of
concerns about the potentially adverse effects of finan-
cial incentives on the quality of people’s decisions to en-
gage in incentivised behaviours. If evidence from this
trial supports such concerns, further research will be
needed to assess how incentives might undermine
informed choice, e.g. whether they alter who attends or
whether they alter the attitudes towards and/or know-
ledge of the target behaviour in all who are offered
incentives and therefore in those who attend. The design
of the present trial does not allow for such assessments
to be made.
Knowledge regarding the impact of financial incentives
both on uptake of the HPV vaccination and on the qual-
ity of decisions to engage in incentivised behaviours is
lacking in the literature. Findings therefore, are expected
to clarify these issues and have the potential to inform
discussions concerning the increasing use of financial
incentives for health promotion.
Research governance
The trial is run by the Birmingham East and North Pri-
mary Care Trust, in partnership with the Young Founda-
tion, as part of the former’s service development. In
consultation with the Trust, it was deemed that ethical ap-
proval was not required for its implementation. Ethical
Approval was sought for researchers at King’s College
London, Centre for the Study of Incentives in Health, to
access data from the Birmingham East and North Primary
Care Trust in order to evaluate the financial incentives
scheme. This was granted by the Birmingham East and
North Research Ethics Committee (reference 11/WM/
0073, 8th April 2011). NHS Permission for Research was
granted by the Birmingham and the Black Country Com-
prehensive Local Research Network (BBC CLRN) Re-
search Management & Governance (RM&G) Consortium
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